400 Drug Companies Blast Court Ruling Nixing Ok Of Abortion Pill

The pharmaceutical industry plunged into a legal showdown over the abortion pill mifepristone, issuing a scorching condemnation of a ruling by a federal judge that invalidated the Food and Drug Administration’s approval of the drug and calling for the decision to be reversed, Pam Belluck and Christina Jewett reported for the New York Times.

Photo Insert: None of the most prominent investment firms and companies which signed the statement make mifepristone, the first pill in the two-drug medication abortion regimen.

The statement was signed by more than 400 leaders of some of the drug and biotech industry’s most prominent investment firms and companies, none of which make mifepristone, the first pill in the two-drug medication abortion regimen.

It shows that the reach of this case stretches far beyond abortion. Unlike Roe v. Wade and other past landmark abortion lawsuits, this one could challenge the foundation of the regulatory system for all medicines in the United States.

WEEKLY FEATURE : MVP Group Keeps Lights On During Pandemic